Ipsen SA ADR (IPSEY)
Ipsen SA ADR is a depositary receipt representing common stock of Ipsen S.A., a biopharmaceutical company headquartered in Paris, France, and listed on OTC Markets. Through the ADR, investors gain exposure to the foreign issuer, which develops and commercializes medicines in oncology, rare disease, and neuroscience. Ipsen’s oncology portfolio includes Somatuline, Cabometyx, Onivyde, Decapeptyl, and several pipeline programs such as Tazverik, tovorafenib, IPN01194, and IPN01195. In rare disease, its portfolio includes Bylvay, Iqirvo, NutropinAq, Increlex, Fidrisertib, and Ritivixibat. The neuroscience franchise includes Dysport and IPN10200. The company also has a development partnership with Simcere Zaiming Pharmaceutical Co., Ltd. for SIM0613.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-IPSE.Y
|
$53.94
|
22.4% Upside
|
Undervalued
|
—
|
—
|
—
|
Great
|
—
|
—
|
0.34
|
0.8%
|
July 30, 2026
|
29.8x
|
3.1x
|
3.4x
|
15.192 B
|
14.695 B
|
6.8%
|
36.4%
|
9.3
|
26.2%
|
233.0%
|
